Barclays had a $3.75 billion est for Q2 Solvaldi sales, which is far more realistic than these lowball
estimates that makje no sense whatsoever. Look at the piddly scripts in the first part of Q1, take into account that you had far less existing patients to renew their scripts, there is no way that Q2 is going to come under 50% more than Q1. At least Barclays accounts for a 65% increase.
The $3.75 billion Solvaldi number would put EPS in the $2 range, or, meedless to say, $8 EPS on an annualized basis.